StratDeck

Two stocks in Drug Manufacturers - General

Novartis vs Novo Nordisk A/S: profit, growth, debt and price compared

Novo Nordisk A/S is stronger on 5 of 7 figures: profit margin, sales growth, debt, price for its expected profit and dividend. Novartis is stronger on 1: price trend.

Figures as of 18 November 2026Yahoo Finance
Explore Novartis' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Novartis and Novo Nordisk A/S side by side
NovartisNOVN.SWNovo Nordisk A/SNOVO-B.CO
Net margin17.5%Stronger: 33.9%
Revenue growth, past year+4.70%Stronger: +5.60%
Debt to equity128.6%Stronger: 61.7%
Forward P/E15.9×Stronger: 12.0×
Dividend yield2.78%Stronger: 4.25%
AnalystsHold · 22Hold · 24
From its 200-day averageStronger: +9.2%−7.0%

Share price over the past year

  • Novartis+25.9%
  • Novo Nordisk A/S−12.7%

14 Nov 202518 Nov 2026

Novartis or Novo Nordisk A/S: which is stronger?

  • NOVO-B.CO

    Which is more profitable?

    Novo Nordisk A/S keeps more of each sale as profit: 33.9% against 17.5%.

  • NOVO-B.CO

    Which is growing its sales faster?

    Novo Nordisk A/S is growing its sales faster: +5.60% over the past year, against +4.70%.

  • NOVO-B.CO

    Which has borrowed less?

    Novo Nordisk A/S has borrowed less: its debt is 61.7% of what its shareholders own, against 128.6% for Novartis.

  • NOVO-B.CO

    Which costs less for the profit it is expected to make?

    Novo Nordisk A/S costs less for the profit it is expected to make: 12.0× its forward earnings, against 15.9×.

  • NOVO-B.CO

    Which pays more in dividends?

    Novo Nordisk A/S pays more back in dividends for what a share costs: 4.25% a year, against 2.78%.

  • Which do analysts rate higher?

    Analysts rate both the same: Hold.

  • NOVN.SW

    Which is in the stronger price trend?

    Novartis' price is in the stronger trend: 9.2% above its 200-day average, against 7.0% below.

What each company does

NOVN.SWNovartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Reports results on 3 February 2027

NOVO-B.CONovo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.